hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessa

StephenW

    Arch Virol. 2011 Nov 15.
http://www.ncbi.nlm.nih.gov/pubmed/22080196
A prospective clinical study in hepatitis B e antigen-negative chronic
hepatitis B patients with stringent cessation criteria for adefovir. Ha M,
Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W,
Huang Z. Department of Infectious Diseases and Hepatology, Shanghai No 7
hospital, Pudong Gaoqiao Datong Road 358, Shanghai, 200137, China,
[email protected].

Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but
its effectiveness after cessation is still unknown. This study was to
evaluate the effectiveness of adefovir treatment with strict cessation
criteria in hepatitis B e antigen (HBeAg)-negative patients and to identify
potentially important factors. One hundred forty-five HBeAg-negative CHB
patients who had received adefovir treatment for at least 24 months and for
whom serum hepatitis B virus (HBV) DNA had remained undetectable for at
least 18 months before cessation were included. They were followed up
monthly during the first four months and at 3-month or 6-month intervals
thereafter. Patients with ≥10(4) copies of HBV DNA per mL were defined as
relapsed. In total, 95 patients relapsed within the follow-up time, and
more than 93% relapsed within 12 months after adefovir cessation.
Cumulative relapse rates at months 6, 12, 24, 36, 48 and 60 were 53.8%,
61.4%, 65.5%, 65.5%, 65.5% and 65.5%, respectively. Age was the only factor
associated with relapse, with lower relapse rates in younger patients shown
by Cox regression analysis. HBsAg seroconversion occurred in 12 patients,
and none of them relapsed during follow-up. The effectiveness of adefovir
therapy does not persist in HBeAg-negative CHB patients, even when strict
cessation criteria are applied, except for patients aged ≤ 25 years.
HBsAg seroconversion is the ideal endpoint of adefovir treatment.

StephenW

拱Virol。 2011年11月15日。
http://www.ncbi.nlm.nih.gov/pubmed/22080196
的前瞻性临床研究乙型肝炎e抗原阴性的慢性
乙型肝炎患者阿德福韦严格的停止标准。哈中号，
张国伟，刁小号，林M，旭日升，她H，关彗星，沉大号，黄C，沉渭，
黄Z。传染病和肝病，上海7
医院，上海，浦东高桥大同路358，200137，中国，
[email protected]。

阿德福韦通常适用于治疗慢性乙型肝炎（CHB），但
其停止后的成效仍是未知数。本研究
阿德福韦治疗的效果评估与严格戒烟
乙肝e抗原（HBeAg）阴性患者的标准，并确定
潜在的重要因素。一百四十五个的HBeAg阴性CHB
谁收到了至少24个月，阿德福韦治疗的患者
人血清乙肝病毒（HBV）DNA仍然检测不到在
被列入了至少18个月前停止。他们随访
每月在今年前四个月，并在3个月或6个月的时间间隔
其后。被定义为患者≥10（4）每毫升HBV DNA的副本
复发。总共有95例患者复发的随访时间内，
阿德福韦停止后12个月内复发的93％以上。
在6个月，12，24，36，48和60的累积复发率分别为53.8％，
61.4％，65.5％，65.5％，65.5％和65.5％。年龄是唯一的因素
与复发，与年轻显示患者的复发率较低
Cox回归分析。发生在12例乙肝表面抗原血清学转换，
随访期间没有复发。阿德福韦的有效性
不坚持治疗HBeAg阴性的慢性乙型肝炎患者，即使严格
应用停止标准，年龄≤25岁的患者除外。
乙肝表面抗原血清学转换是阿德福韦治疗的理想终点。